



Universiteit
Leiden
The Netherlands

A screening based approach to find new paths for targeted treatment in chondrosarcoma

Jong, Y. de

Citation

Jong, Y. de. (2020, September 2). *A screening based approach to find new paths for targeted treatment in chondrosarcoma*. Retrieved from <https://hdl.handle.net/1887/136273>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/136273>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/136273> holds various files of this Leiden University dissertation.

Author: Jong, Y. de

Title: A screening based approach to find new paths for targeted treatment in chondrosarcoma

Issue Date: 2020-09-02

Curriculum vitae

Yvonne de Jong was born on August 13, 1988 in Gouda, the Netherlands. She followed Havo (Nature and Health track) at the Goudse waarden in Gouda. Directly after her graduation in 2006 she started to study Biology and medical laboratory research at the university of applied sciences in Leiden followed by a pre-master and master Biomedical sciences at Leiden university of which she graduated in 2013. She performed several internships during her bachelor studies in diagnostics as well as in research, with her final internship being at the tumour genetics department at the Leiden University Medical Centre supervised by Dr. E.C. Robanus-Maandag, where she characterized tumours that developed in mice with a defect in Wnt signalling specifically in smooth muscle cells. During the first year of her masters she worked on improving osteo-inductive properties of titanium implants at the department of orthopaedics at Erasmus MC, with Dr. J. van der Stok as supervisor. During her second year she started with an internship at the department of pathology at the Leiden University Medical Centre working on identification of genes involved in osteosarcoma progression by studying transformed mesenchymal stem cells supervised by Dr. A.M. Cleton-Jansen. Later she switched towards chondrosarcoma research, because she was appointed as a PhD student in the Bone and soft tissue tumour group, led by Prof. Dr. J.V.M.G. Bovée. The results of this research are presented in this thesis. Currently she is working as a post-doc in the group of Dr. J.C. Dorsman, at the Oncogenetics department of the Amsterdam university medical centre, location VUMC, investigating genetic events that play a role in the initiation and progression of retinoblastoma.

List of publications

Venneker S, Kruisselbrink AB, Briare-de Bruijn IH, **de Jong Y**, van Wijnen AJ, Danen EHJ, Bovée JVMG, Inhibition of PARP sensitizes chondrosarcoma cell lines to chemo- and radiotherapy irrespective of the *IDH1* or *IDH2* mutation status. *Cancers (basel)* 2019 Dec 2;11(12)

de Jong Y, Bennani F, van Oosterwijk JG, Alberti G, Baranski Z, Wijers-Koster P, Baelde H, Cleton- Jansen AM, van de Water B, Corver W, Danen EHJ, Bovée JVMG, A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival. *J Bone Oncol.* 2019 Nov 17; 19:100268

de Jong Y, Ingola M, Briare-de Bruijn I, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs B, Cleton-Jansen AM, Haas R, Bovée JVMG, Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. *Clin Sarcoma Res.* 2019 May 28;9:9.

de Jong Y*, Addie RD*, Alberti G, Cleton-Jansen AM, Corver W, Morreau H, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG, Exploration of the chondrosarcoma metabolome; mTOR pathway as an important pro-survival pathway. *J Bone Oncol.* 2019 Jan 29;15:100222.

de Jong Y, Monderer D, Brandinelli E, Monchanin M, van den Akker BE, van Oosterwijk JG, Blay JY, Dutour A , Bovée JVMG, Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. *Oncogenesis.* 2018 Sep 21;7(9):74

de Jong Y., Bovée JVMG Molecular Drivers in Chondrosarcoma. In: Harsh G.R., Vaz-Guimaraes F., editors. *Chordomas and Chondrosarcomas of the Skull Base and Spine.* Elsevier: Academic Press; 2018:31–41.

Peterse EFP, Niessen B, Addie RD, **de Jong Y**, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG, Targeting glutaminolysis in chondrosarcoma in context of the *IDH1/2* mutation. *Br J Cancer.* 2018 Apr;118(8):1074-1083

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, **de Jong Y**, Danen EHJ, Cleton- Jansen AM, Bovée JVMG, NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma. *Mol Cancer Res.* 2017

De Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, **de Jong Y**, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG, High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin is Essential for Tumor Growth. *Transl Oncol.* 2017 Aug;10(4):546-554

De Jong Y, van Maldegem AM, Marino-Enriquez A, de Jong D, Suijker J, Briaire-de Bruijn IH, Kruisselbrink AB, Cleton-Jansen AM, Szuhai K, Gelderblom H, Fletcher JA, Bovée JVMG, Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. *Lab Invest* 2016 Oct;96(10):1128-37

Peterse EFP, Cleven AH, **de Jong Y**, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JVMG, No preclinical rationale for IGFIR directed therapy in chondrosarcoma of bone. *BMC Cancer* 2016 Jul 14;16:475

Speetjes FM, **de Jong Y**, Gelderblom H, Bovée JVMG, Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. *Curr Opin Oncol.* 2016 Jul;28(4):314-22

De Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JVMG, Targeting survivin as a potential new treatment for chondrosarcoma of bone. *Oncogenesis* 2016 May 9;5:e222

Baranski Z, Booij TH, Kuijjer ML, **de Jong Y**, Cleton-Jansen AM, Price LS, van de Water B, Bovée JVMG, Hogendoorn PC, Danen EH. MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. *Genes Cancer* 2015 Nov;6(11-12):503-12

Baranski Z, **de Jong Y**, Ilkova T, Peterse EFP, Cleton-Jansen AM, van de Water B, Hogendoorn PC, Bovée JVMG, Danen EH. Pharmacological inhibition of Bcl-xl sensitizes osteosarcoma to doxorubicin. *Oncotarget* 2015 Nov 3;6(34):36113-25

Nawoord

Er zijn veel mensen die hebben geholpen bij het tot stand komen van dit proefschrift en die zou ik graag willen bedanken. Als allereerst wil ik graag mijn promotor Judith Bovée bedanken voor het vertrouwen en de kansen die ik heb gekregen om al deze projecten te kunnen doen en afronden. Ook wil ik graag mijn co-promotor Erik Danen bedanken voor de hulp, discussies en ideeën voor follow-up experimenten. Verder wil ik graag ook Anne-Marie Cleton-Jansen bedanken voor alle hulp en support waar nodig.

Alle (oud) collega PhDs, analisten, groepshoofden, post-docs en studenten van de afdeling pathologie wil ik ook graag bedanken voor alle hulp in het lab, discussies, maar ook alle gezelligheid tijdens de pauzes en activiteiten die buiten werk georganiseerd werden. Verder wil ik ook de mensen van andere labs en instituten in binnen en buitenland bedanken voor de goede samenwerkingen. Daarnaast wil ik mijn huidige collega's, vrienden en familie ook graag bedanken voor hun support, zeker de afgelopen tijd.

Als laatste wil ik mijn vader Arie, mijn moeder Willy, oma Tuynder en mijn broers Robin, Leon en Arjen heel erg bedanken. Robin je bent dan niet meer hier, maar je blijft voor altijd bij ons. Liefde is Sterker dan de Dood.

